Andrew J Sauer MD

Cardiologist @MidAmericaHeart, building programs to implement therapies, advance discovery, and foster innovation for patients suffering from heart disease.

[Andrew J Sauer MD @AndrewJSauer]

My top ten tips for graduating fellows and faculty entering and continuing “early career” as I am transitioning into “mid-career”. A thread:

[Journal of Cardiac Failure @JCardFail]

AI meets Heart Failure in the November issue of JCF 🫀

Our Focus Issue, Artificial Intelligence and Heart Failure: A Critical Juncture, explores the opportunities and challenges of AI in heart failure research and care.

Read the full issue: https://t.co/57AlG1pnbr

[Andrew J Sauer MD @AndrewJSauer]

https://t.co/fZ3vQmLymD

[NEJM @NEJM]

Presented at #ScientificSessions26:

In patients with atrioventricular block, left bundle-branch pacing resulted in a lower incidence of a composite of death, hospitalization for heart failure, or pacing-induced cardiomyopathy than right ventricular pacing. Full OptimPacing trial results: https://t.co/Fg0lv9xcka

@AHAScience

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

💉 CAMEO-SEMA
👥 81 with obesity + HFpEF; 58% women
⚖️ Semaglutide vs placebo
📊 52wk exercise PAWP −10.6 mmHg (95% CI −13.3 to −8.0)
✅ Mechanistic support; small trial
🔗 https://t.co/QczdsBD0gI
#AHA26 #ScientificSessions26 #CVPrev

[Yogesh Reddy @yreddyhf]

Are people with obesity and HFpEF getting better with glp1 drugs because their hearts are better, or is it just feeling better from wt loss? Two companion papers @NatureMedicine from placebo controlled RCT show that their HF really is better with pcwp and LA strain by MRI.

[Henry Han @HanCardiomd]

Effects of #Sotatercept on Cardiac Structure and Function in Combined Post- and Precapillary Pulmonary Hypertension in #HFpEF : Analysis of the #CADENCE Study

https://t.co/ILOT5CcRz8

#ScientificSessions26 @AHAScience @AHAMeetings @CircAHA

[Robert Mentz, MD @robmentz]

Congrats @GLewisCardiol & team for important study of IV iron w FDI in HFpEF. Improving peak VO2 and other pt centered endpoints. Fun to write accompanying editorial

Now we need to finish ICONIC and INFUSE
@FudimMarat @AndrewPAmbrosy @DCRINews #ScientificSessions26

[NEJM @NEJM]

Presented at #ScientificSessions26:

In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-DIABETES trial results: https://t.co/8LPXfkfp2R

@AHAScience

[Sanjay Kaul @kaulcsmc]

When a claim of noninferiority hides factual inferiority!

Data do not support statin discontinuation is safe with respect to MACE.

[NEJM @NEJM]

Trending on https://t.co/YGfDrRsIhE:

𝐓𝐀𝐕𝐑 𝐢𝐧 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐌𝐨𝐝𝐞𝐫𝐚𝐭𝐞 𝐀𝐨𝐫𝐭𝐢𝐜 𝐒𝐭𝐞𝐧𝐨𝐬𝐢𝐬 𝐰𝐢𝐭𝐡 𝐀𝐭-𝐑𝐢𝐬𝐤 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐬 (𝐏𝐑𝐎𝐆𝐑𝐄𝐒𝐒 𝐓𝐫𝐢𝐚𝐥) by P. Généreux et al.

In patients with moderate aortic stenosis and at-risk features, the percentage who died or had a heart-failure event within 2 years was lower with transcatheter aortic-valve replacement than with surveillance (16.7% vs. 23.9%).

Read the article: https://t.co/Ux6ThWHfV5

[Gregg Fonarow MD @gcfmd]

💊 Quadruple GDMT for HFrEF at Cost Plus generic prices:

💵 $0.79/day · $23.83/mo · $290/yr

📉 ↓87% HF 🏨, ↓61% all-cause 🏨

🏥 Avoided hospital costs dwarf the drug cost

✅ Extraordinary value.

🎯 Get every eligible patient on all 4! ❤️

#GDMT @costplusdrugs @mcuban

[Robert Mentz, MD @robmentz]

Thank you, @AHajduczok, for having me on your podcast!

Will I ever listen to it? Absolutely not. 😂 Nothing more uncomfortable than listening to yourself talk. But hopefully there are a few pearls of wisdom buried in here @DukeHeartCenter @DCRINews @DrMarthaGulati @dranulala

[Andrew J Sauer MD @AndrewJSauer]

Reminder, #AHA26 I’m hosting a reception from 5-8 pm tonight. If you are interested in discussing clinical trials, especially finerenone and heart failure, come by for cocktails and high quality apps on me!

[Andrew J Sauer MD @AndrewJSauer]

Heading to AHA Scientific Sessions 2026 in Chicago?

I’d love to connect with colleagues interested in what’s next for finerenone in heart failure on Friday evening.

I’m extending an open invitation to investigators, clinicians, and research teams to join us at the University Club of Chicago to learn how the MOONRAKER program is moving forward—and explore opportunities to contribute to this work.

Building on FINEARTS-HF, three complementary phase 3 trials are addressing questions that matter in everyday clinical practice:

• REDEFINE-HF: Evaluating whether finerenone reduces cardiovascular death and first and recurrent HF events in patients hospitalized with acute heart failure and LVEF ≥40%. This will extend the evidence into the vulnerable period surrounding an HF hospitalization.

• CONFIRMATION-HF: Testing an early treatment strategy combining finerenone with an SGLT2 inhibitor across the EF spectrum, assessing whether this approach improves clinical outcomes and patient-reported symptoms compared with usual care following an HF hospitalization.

• FINALITY-HF: Evaluating finerenone in patients with HFrEF who are intolerant of or ineligible for steroidal MRAs, generating evidence on cardiovascular death, HF events, symptoms, and safety in a population with an important unmet treatment need.

Together, these studies will clarify where finerenone fits across HF populations and care settings, including its role in early combination therapy and in patients with limited treatment options.

I’m proud of our Saint Luke's Mid America Heart Institute team’s collaboration with Marc Bonaca, CPC Clinical Research, and investigators worldwide to advance this program.

Whether you’re already involved in MOONRAKER, interested in research collaboration, or simply want to learn more, please join us for an evening of conversation and connection.

📍 University Club of Chicago
76 East Monroe Street, Chicago

Message me for reception details and RSVP. I look forward to seeing you in Chicago!

[EHJ Editor-in-Chief @ehj_ed]

The Role of Long-acting glucagon-like peptide-1 receptor agonists in Heart Failure with Preserved Ejection Fraction: Weight Loss-Dependent and Independent Effects!

https://t.co/WHDN0IcaEn

#EHJ #incretin #therapy #heart #failure #cardiotwitter @ESC_Journals @escardio

[OpenSource Cardiology @opensourcecards]

CMR GUIDE, the first randomized test of scar-guided ICD therapy at LVEF 36% to 50%, lowered sudden death (1.7% vs 5.8%) but not all-cause mortality (11.1% vs 11.0%), and added harms. Scar alone should not yet prompt an ICD.

@ramziw_ @tamarappoo

https://t.co/FhObmlue6R

[Historic Vids @historyinmemes]

“I can't stand it to think my life is going so fast and I'm not really living it.”

- Ernest Hemingway, The Sun Also Rises

Life moves faster than we realize, and it’s easy to get caught in routines that leave us feeling disconnected from the moments that matter. Staying busy doesn’t necessarily mean we’re truly living. Before we know it, days turn into years as we wait for the perfect time to start enjoying life.

A meaningful life comes from being present, taking chances, building relationships, and creating memories. We may not be able to control how quickly time passes, but we can control how fully we experience it. Don’t spend your entire life getting ready to live.

[Jenna Skowronski MD @JennaSkowronski]

Can’t wait for this debate with @BrazileTiffany! See you in Chicago on November 7 following the #AHA26 Scientific Sessions for a @CardioNerds Face Off punch🥊

Register here: https://t.co/c3cIg82gQR
#CardioNerds #CardioNerdsFaceOff

[Alexander Hajduczok, MD 🇺🇦🙏 @AHajduczok]

Episode 6: Moving the Needle in Medicine w/ guest @robmentz is now live!

We talk all things mentorship, career challenges both inside and outside of the hospital, building teams, heart failure leadership, and taking over as editor-in-chief for the @JCardFail. Check it out!!!

https://t.co/MZsXkEHD3p

[Ahmed Bennis MD 🫀 @drbennisahmed]

Hydralazine-isosorbide dinitrate in chronic heart failure with reduced ejection fraction: the H-HeFT trial

Hydralazine-isosorbide dinitrate did not change the incidence of the composite endpoint of heart failure events or death in patients with heart failure and LVEF ≤40%.
@HFA_President @hfcollaboratory @gcfmd @MasriAhmadMD @gcfmd @SJGreene_md
https://t.co/wyWSf3bFsN

[Alexander Hajduczok, MD 🇺🇦🙏 @AHajduczok]

Similar to our episode with @AndrewJSauer, @robmentz emphasizes quality over quantity. But also stresses the importance of balance and giving one’s self grace.